Diagnostic tests for medullary thyroid carcinoma: an umbrella review

Endocrine. 2023 Aug;81(2):183-193. doi: 10.1007/s12020-023-03326-6. Epub 2023 Mar 6.

Abstract

Purpose: To summarize the more robust evidence about the performance of tools useful for diagnosis of medullary thyroid carcinoma (MTC) such as calcitonin (Ctn) and other circulating markers, ultrasound (US), fine-needle aspiration (FNA), and other imaging procedures.

Methods: This systematic review of systematic reviews was carried out according to a predefined protocol. A search string was created. An electronical comprehensive search of literature was performed on December 2022. Quality assessment of eligible systematic reviews was performed and main findings were described.

Results: Twenty-three systematic reviews were included and several findings were achieved. Ctn is the most reliable diagnostic marker of MTC with no evidence of improvement with stimulation test. CEA doubling time is more reliable than Ctn in identifying MTC with poorer prognosis. US sensitivity is suboptimal in MTC and only just over half of cases are at high risk according to Thyroid Imaging And Reporting Data Systems. Cytology can correctly detect MTC in just over half of cases and measuring Ctn in washout fluid from FNA is necessary. PET/CT is useful for detecting recurrent MTC.

Conclusions: Future guidelines of both thyroid nodule management and MTC diagnosis should consider these evidence-based data.

Keywords: Calcitonin; FNA; Medullary thyroid carcinoma; PET; Ultrasound.

Publication types

  • Review
  • Systematic Review

MeSH terms

  • Biopsy, Fine-Needle
  • Calcitonin / blood
  • Diagnostic Tests, Routine* / methods
  • Positron Emission Tomography Computed Tomography
  • Systematic Reviews as Topic
  • Thyroid Neoplasms* / diagnosis
  • Thyroid Nodule* / diagnostic imaging
  • Thyroid Nodule* / pathology

Substances

  • Calcitonin

Supplementary concepts

  • Thyroid cancer, medullary